Skip to main content
. 2018 Sep 24;53(Suppl 1):19–144. doi: 10.1038/s41409-018-0318-y
Age/Sex 6/M 10/M 6/M 2/F 26/F 6/M 31/F 14/M
Post Allo-HSCT Relapse(Months) 24 9 29 7 1 2 3 3.5
Blasts in BM(%) 68 75 16 69 1 34.5 59 7.5
Follow-up Day 345 218 167 124 119 99 90 83
Dose/kg 1x106 1x106 1x105 3x105 3x105 3x105 1x105 1x105 2x105 3x105
CAR-T Cells Donor Auto Auto Donor Donor Donor Auto Auto
CRS Grade IV III III I I I II I
GVHD after CAR-T No No No aGVHD(II) No Mild cGVHD No No
Initial Response CR CR CR NR CR CR CR CR
Outcome Relapse on day 167 2nd allo-HSCT Remain CR Relapse on day 98 Other therapy Remain CR Remain CR MLL-AF4 0.02% on day 75 Remain CR